Gilead Sciences Q4 2023 Adj EPS $1.72 Misses $1.76 Estimate, Sales $7.10B Inline
Portfolio Pulse from Benzinga Newsdesk
Gilead Sciences (GILD) reported Q4 2023 adjusted EPS of $1.72, missing the consensus estimate of $1.76 by 2.27%. Quarterly sales were $7.10 billion, in line with estimates but down 3.91% from the same period last year.
February 06, 2024 | 9:03 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Gilead Sciences reported a slight miss in Q4 2023 EPS and sales in line with estimates but showing a year-over-year decline.
The miss in EPS, even if slight, combined with a year-over-year decline in sales, could lead to negative investor sentiment in the short term. However, the fact that sales met estimates might mitigate some of the negative impact.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100